Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …

Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib,
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …

Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …

Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

PURPOSE: The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …

Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a
significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of …

The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in
the treatment of advanced nonsmall-cell lung cancer (NSCLC), but the median survival of …

Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …